

## **Metformin hydrochloride (Glucophage SR<sup>®</sup>) prolonged-release tablet**

**Merck Serono Ltd**

**August 2017**

### **Statement of Advice**

**In the absence of a submission from the holder of the marketing authorisation, metformin hydrochloride (Glucophage SR<sup>®</sup>) cannot be endorsed for use within NHS Wales for the reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT and/or IFG, and/or increased HbA1C who are: at high risk for developing overt type 2 diabetes mellitus and; still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months. Treatment with Glucophage SR<sup>®</sup> must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk. Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.**

#### **Advice context:**

The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication of effort, AWMSG would not normally consider undertaking an appraisal if NICE intends to publish final technology appraisal guidance (STA/MTA/HST) for the same product and indication(s) within 12 months of the date of marketing authorisation. AWMSG guidance is interim to that of NICE, should NICE subsequently publish guidance.

The above medicine cannot be endorsed for use within NHS Wales as a technology appraisal by NICE or AWMSG has not been undertaken. The medicine should NOT be prescribed routinely within NHS Wales for the indication stated above.

In the absence of guidance issued by NICE or AWMSG, clinicians should continue to exercise their clinical judgement when providing care for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.

This statement will be removed on receipt of a submission (i.e. the full submission [Forms A and B] or limited submission [Forms A and C]), or updated when final NICE technology appraisal guidance becomes available.